Parabilis Medicines Appoints Dr. Craig L. Tendler to Board
Biotechnology
Change of Management
IPO:
Jun 10, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Parabilis Medicines Appoints Dr. Craig L. Tendler to Board of Directors
CAMBRIDGE, Mass., USA - Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases by unlocking undruggable targets, announced the appointment of Craig L. Tendler, M.D., to its Board of Directors.
... Read on — Members only
About Parabilis Medicines, Inc.
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
